The pivotal role of FOXC2 in prostate cancer was demonstrated by indirect suppression of FOXC2 in mice injected with a metastatic prostate cancer cell line, restoring epithelial phenotype, attenuating CSCs and, of major significance, resensitising prostate carcinoma cells to anti‐androgen and taxane therapy 50. Here, FOXC2 is linked to prostate cancer.